Written by MATTHEW PERRONE
What does full approval of Pfizer’s COVID-19 vaccine mean?
It means Pfizer’s shot for people 16 and older has now undergone the same rigorous testing and regulatory review as dozens of other long-established vaccines.
COVID-19 vaccines in the U.S. were initially rolled out under the Food and Drug Administration’s emergency use authorization, which allows the agency to speed the availability of medical products during public health emergencies.
Under the process, the FDA waived some of its normal data requirements and procedures to make the COVID-19 vaccines available months earlier than would have been possible under normal circumstances.
Pfizer’s vaccine — along with those from Moderna and Johnson & Johnson — still underwent testing in tens of thousands of people to establish safety and effectiveness against COVID-19. But the FDA initially required the companies to submit about only two months of safety monitoring data on study participants, the period when side effects are most likely to occur.
For full approval, the FDA required six months of follow-up data. FDA inspectors also visited the plants where the vaccines are made and reviewed each step of the production process for extra assurance that the shots are made under safe, sterile conditions.
Because vaccines are typically given to otherwise healthy individuals, they are generally subject to more regulatory scrutiny than other medical products, including prescription drugs. Full approval means the Pfizer vaccine now carries the FDA’s strongest endorsement of safety and effectiveness.
Public health experts hope the change will convince more unvaccinated people to get the shot and spur more employers to require vaccinations.
Moderna has also applied for full approval, and Johnson & Johnson has said it hopes to apply later in the year.
Pfizer’s shot still is available for 12- to 15-year-olds under emergency use authorization. The full approval also doesn’t apply to boosters. The agency will decide separately whether an extra shot is necessary for healthy people.
Related Stories
‹

US Expands COVID Boosters to All Adults, Final Hurdle AheadWritten by LAURAN NEERGAARD and MATTHEW PERRONE U.S. regulators on Friday moved to open up COVID-19 booster shots to all adults, expanding the government’s campaign to shore up protection and get ahead of rising coronavirus cases that may worsen with the holidays. Pfizer and Moderna announced the Food and Drug Administration’s decision after at least […]
![]()
U.S. Parents Excited Over Prospect of Virus Shots for ChildrenWritten by HEATHER HOLLINGSWORTH and TODD RICHMOND After more than a year of fretting over her 13-year son with a rare liver disease, Heather Ousley broke into tears when she learned that he and millions of other youngsters could soon be eligible for the COVID-19 vaccine. “This day is the best day in the history of […]

U.S. Allows Emergency COVID-19 Vaccine in Bid to End PandemicThe U.S. gave the final go-ahead Friday to the nation’s first COVID-19 vaccine, marking what could be the beginning of the end of an outbreak that has killed nearly 300,000 Americans. Shots for health workers and nursing home residents are expected to begin in the coming days after the Food and Drug Administration authorized an […]

Moderna Sues Pfizer Over Patents Behind COVID-19 VaccineWritten by TOM MURPHY COVID-19 vaccine maker Moderna is suing Pfizer and the German drugmaker BioNTech, accusing its main competitors of copying Moderna’s technology in order to make their own vaccine. Moderna said Friday that Pfizer and BioNTech’s vaccine Comirnaty infringes on patents Moderna filed several years ago protecting the technology behind its preventive shot, […]
![]()
Moderna Seeks FDA Authorization for 4th Dose of COVID ShotWritten by ZEKE MILLER Drugmaker Moderna asked the Food and Drug Administration on Thursday to authorize a fourth shot of its COVID-19 vaccine as a booster dose for all adults. The request is broader than rival pharmaceutical company Pfizer’s request earlier this week for the regulator to approve a booster shot for all seniors. In […]

Pfizer, US Ink $5.29B Deal for Possible COVID-19 TreatmentWritten by TOM MURPHY The U.S. government will pay drugmaker Pfizer $5.29 billion for 10 million treatment courses of its potential COVID-19 treatment if regulators authorize it, the nation’s largest purchase agreement yet for a coronavirus therapy. Pfizer asked the Food and Drug Administration on Tuesday to authorize emergency use of the experimental pill, which […]
![]()
Pfizer Says COVID-19 Pill Cut Hospital, Death Risk by 90%Written by MATTHEW PERRONE Pfizer Inc. said Friday that its experimental antiviral pill for COVID-19 cut rates of hospitalization and death by nearly 90% in high-risk adults, as the drugmaker joins the race to bring the first easy-to-use medication against the coronavirus to the U.S. market. Currently all COVID-19 treatments used in the U.S. require […]

US Gives Final Clearance to COVID-19 Shots for Kids 5 to 11U.S. health officials on Tuesday gave the final signoff to Pfizer’s kid-size COVID-19 shot, a milestone that opens a major expansion of the nation’s vaccination campaign to children as young as 5. The Food and Drug Administration already authorized the shots for children ages 5 to 11 — doses just a third of the amount […]

Pfizer Asks US To Allow COVID Shots for Kids Ages 5 to 11Written by LAURAN NEERGAARD Pfizer asked the U.S. government Thursday to allow use of its COVID-19 vaccine in children ages 5 to 11 — and if regulators agree, shots could begin within a matter of weeks. Many parents and pediatricians are clamoring for protection for children younger than 12, today’s age cutoff for the vaccine […]
![]()
What Does Full Approval of Pfizer’s COVID-19 Vaccine Mean?Written by MATTHEW PERRONE What does full approval of Pfizer’s COVID-19 vaccine mean? It means Pfizer’s shot for people 16 and older has now undergone the same rigorous testing and regulatory review as dozens of other long-established vaccines. COVID-19 vaccines in the U.S. were initially rolled out under the Food and Drug Administration’s emergency use […]
›